Status:
COMPLETED
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
Lead Sponsor:
Bayer
Conditions:
Contrast Enhanced X-ray Based Examination
Eligibility:
All Genders
Brief Summary
This is an observational study in which patient data from the past of people who received Ultravist prior to an X-ray based scan are studied. In observational studies, only observations are made with...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients of all age groups which were referred to any iodine-based contrast-enhanced procedure after administration of either Ultravist 300 mg I/mL or 370 mg I/mL.
Exclusion
Key Trial Info
Start Date :
June 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 28 2022
Estimated Enrollment :
152233 Patients enrolled
Trial Details
Trial ID
NCT05428397
Start Date
June 30 2022
End Date
October 28 2022
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Wuppertal, Germany, 42096